Back to search

University of Crete (UOC)

Delineation of the mechanisms that promote the tolerogenic properties of dendritic cells in autoimmune diseases

Abstract

dc:description

Autoimmune diseases develop upon aberrant activation of lymphocytes mainly due to failure of self-tolerance mechanisms. Both innate and adaptive immune system over-activation contribute to autoimmunity and tissue inflammation. Rheumatoid arthritis (RA) is considered as an autoimmune disease against post-translationally modified proteins, characterized by uncontrolled inflammation. Genetic data have revealed CD4+ lymphocytes and dendritic cells (DCs) as important contributors to the breach of immunologic tolerance and development of autoimmunity in RA patients. Currently biologic therapies (bDMARDs) applied in clinical practice, mainly target the inflammatory process, such as anti-tumor necrosis factor α (TNF-α)- agents, Interleukin 6 receptor (IL-6R) and JAK-STATs inhibitors, or target the adaptive immune response via B-cell depletion (anti- CD20 antibodies) and T-cell co-stimulation molecule blockade (CTLA4-Ig). Nevertheless, data from registries and cohort studies have shown that in clinical practice, 50-60% of RA patients starting a bDMARD will stop treatment due to inefficacy or toxicity in the long-term, while clinical response, remission or low disease activity, is unpredictable and is achieved by 20-40% of patients. Development of predictive markers of response for everyday clinical practice will be an important step in optimizing the treatment of autoimmune diseases. DCs drive the immune responses through their crucial role in the antigen presentation process. The ability of DCs to modulate T-cell responses has made them an interesting target of study for the immunotherapy of autoimmune diseases. Until now, human DC-based therapeutic strategies have mainly relied on ex vivo generated DCs differentiated from peripheral blood (PB) monocytes and have demonstrated limited efficacy in clinical trials. Thus, identifying alternative therapeutic strategies that aim at manipulating human DCs towards an immunoregulatory phenotype may yield improved treatments. Strategies to manipulate DCs to exploit their immunoregulatory potential are currently under investigation. Cytotoxic T lymphocyte antigen 4 (CTLA4) is a negative costimulatory molecule expressed on the T cell membrane and its significant immunoregulatory role in the context of autoimmune diseases is confirmed through the clinical benefit upon CTLA4-Ig treatment (abatacept) in patients with RA. Several studies support that CTLA4 delivers reverse signals on DCs, thus reducing their inflammatory function and enhancing their tolerogenic phenotype. Nevertheless, the molecular mechanisms that are involved in the induction of the tolerogenic phenotype of CTLA4-mediated effects on DCs, have not been extensively studied. In this study we aimed to identify biomarkers that predict clinical responses to etanercept and abatacept, based on either demographic and clinical characteristics or a detailed immunological profiling of PB of RA patients, respectively. We assessed the levels of pathogenic and regulatory cell populations, as well as the sera transcriptome of abatacept-treated RA patients at baseline, on 3rd and 6th month after treatment initiation in order identify a signature of cell populations and sera proteins, that are associated with clinical responses to abatacept. Furthermore, we used CTLA4-Ig as a tool to generate in vitro tolerogenic DCs (tolDCs) and we investigated the intracellular pathways that are implicated in the induction of the tolerogenic phenotype in CTLA4-treated DCs. To address this, human monocytes from healthy donors were isolated and differentiated into DCs. DCs were cultured with CTLA4-Ig and subjected to genome-wide transcriptomics. The anti-inflammatory function of DCs was further assessed. In the observational study, we showed that approximately half of the patients starting etanercept discontinued within the first year of therapy. We observed that treatment inefficacy, which was the most frequent cause of therapy disruption, was associated with female gender, obesity and higher baseline swollen joint count. Moreover, we highlighted that the groups of patients that improved disease activity were overrepresented by males, patients had shorter disease duration and better functional status. Next, focusing on the immunological studies, we found a strong association of high levels of T helper 1 cells (Th1), myeloid- derived suppressor cells (MDSCs) and DCs with a better response to abatacept treatment at 6 months. Moreover, proteomics analysis revealed 10 amongst 303 proteins in peripheral serum to have differential expression according to clinical responses at 6 months. Interestingly, a composite index based on the above described cellular and protein markers showed a high discriminative ability to predict response to abatacept. Furthermore, we revealed that CTLA4-Ig-treated DCs demonstrated significantly upregulated transcriptional levels of anti-inflammatory gene IL10. However, the expression of inflammatory cytokines IL6 and TNFα were decreased, accompanied with reduced T cell proliferation in co-culture experiments, highlighting the immunosuppressive properties of CTLA4-Ig-treated DCs. Interestingly, transcriptomic analysis revealed 1270 differentially expressed genes in CTLA4-mediated tolDCs, the majority of them participated in metabolic processes, specifically in OXPHOS pathway and mitochondrial function. Notably, we confirmed that tolDCs had lower basal OXPHOS and decreased ATP production via Seahorse assays. Furthermore, expression of phosphorylated mammalian target of rapamycin (mTOR) and AKT1, central regulators of metabolism, were increased in CTLA4-mediated tolDCs. Mechanistically, we showed that mTOR controlled the expression of the transcription factor Sp1, which enhanced the expression of anti-inflammatory gene IL10, thus contributing to the regulatory function of CTLA4-mediated tolDCs.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Goutakoli, Panagiota
  • Γουτακόλη, Παναγιώτα

Subjects

dc:subject × 21

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/55324

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Goutakoli, Panagiota; Γουτακόλη, Παναγιώτα. Delineation of the mechanisms that promote the tolerogenic properties of dendritic cells in autoimmune diseases. University of Crete (UOC), 2023. http://hdl.handle.net/10442/hedi/55324